BS HH 002

Drug Profile

BS HH 002

Alternative Names: BS-HH-002; BS-HH-002.SA; HH-002

Latest Information Update: 28 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hangzhou Bensheng Pharmaceutical
  • Class Alkaloids; Antineoplastics; Harringtonines; Small molecules
  • Mechanism of Action Activating transcription factor 3 inhibitors; Activating transcription factor inhibitors; Apoptosis stimulants; Janus kinase-2 inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Polycythaemia vera; Solid tumours

Most Recent Events

  • 28 Jul 2017 Chemical structure information added
  • 01 Apr 2017 BS HH 002 is still undergoing pre-clinical trials for Solid tumours and polycythaemia vera in USA
  • 01 Apr 2017 Pharmacodynamics data from preclinical trials in Solid tumours presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top